行情

PAVM

PAVM

PAVmed
NASDAQ

实时行情|Nasdaq Last Sale

3.810
-0.200
-4.99%
盘后: 3.840 +0.03 +0.79% 16:54 11/26 EST
开盘
3.870
昨收
4.010
最高
3.940
最低
3.740
成交量
112.12万
成交额
--
52周最高
9.70
52周最低
1.630
市值
3.35亿
市盈率(TTM)
-6.5385
分时
5日
1月
3月
1年
5年
InMed Pharmaceuticals, EyePoint Pharmaceuticals leads healthcare gainers; Cassava Sciences, Eloxx Pharmaceuticals among major losers
Gainers: InMed Pharmaceuticals (NASDAQ:INM) +47%, EyePoint Pharmaceuticals (NASDAQ:EYPT) +24%, Varex Imaging (NASDAQ:VREX) +12%, OptiNose (NASDAQ:OPTN) +10%, Talkspace (NASDAQ:TALK) +7%. Losers: Cassava Sciences (NASDAQ:SAVA) -26%, Eloxx Pharmaceuticals (N...
Seekingalpha · 11/17 16:05
由于季度净亏损猛增,Lucid Diagnostics 下跌 18%
Shares of Lucid Diagnostics (LUCD -18.9%) are down sharply today after the company reported that its Q3 2021 net loss widened ~244% to ~$7M (-$0.49 net loss per share, basic
Seekingalpha · 11/17 15:55
Mid-Morning Market Update: Markets Down; Lowe's Earnings Beat Estimates
Following the market opening Wednesday, the Dow traded down 0.34% to 36,017.63 while the NASDAQ fell 0.19% to 15,944.13. The S&P also fell, dropping 0.23% to 4,690.06.
Benzinga · 11/17 15:12
Rivian Automotive, DLocal, StoneCo among premarket losers' pack
PAVmed PAVM -23% on Q3 earnings release. Cyclo Therapeutics CYTH -21% after secures $12M capital through equity raise. Atea Pharmaceuticals AVIR -15% after Roche ending collaboration with Atea on COVID-19 candidate. Arrival ARVL -14% after raises $200M in
Seekingalpha · 11/17 13:36
Lucid Diagnostics to Present at Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced that Dennis McGrath, Chief...
Business Wire · 11/17 13:30
PAVmed down 10% after-hours on quarterly earnings
Shares of PAVmed (NASDAQ:PAVM) are down 10% in after-hours trading after the company's Q3 2021 earnings results missed estimates on revenue, while EPS was in-line. On a non-GAAP basis, the company's net
Seekingalpha · 11/16 22:44
PAVmed EPS in-line, misses on revenue
PAVmed (NASDAQ:PAVM): Q3 Non-GAAP EPS of -$0.10 in-line; GAAP EPS of -$0.15 misses by $0.02. Revenue of $0.2M misses by $0.08M. Press Release
Seekingalpha · 11/16 22:02
PAVmed lags consensus with early revenue estimates for Q3
PAVmed (NASDAQ:PAVM) shares have lost ~6.7% in the post-market after the company disclosed preliminary financial results for the third quarter of 2021 that fell short of Street forecasts. The company has recorded
Seekingalpha · 11/16 21:41
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解PAVM最新的财务预测,通过PAVM每股收益,每股净资产,每股现金流等数据分析PAVmed近期的经营情况,然后做出明智的投资选择。
分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

0.00%强力推荐
100.00%买入
0.00%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测PAVM价格均价为10.00,最高价位12.00,最低价为8.00。
最高12.00
均价10.00
最低8.00
现价3.810
EPS
实际EPS
预期EPS
-0.14-0.10-0.07-0.03
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
机构持股
总机构数: 116
机构持股: 2,355.26万
持股比例: 26.79%
总股本: 8,793.04万
类型机构数股数
增持
35
257.96万
建仓
27
128.89万
减持
28
76.99万
平仓
18
68.79万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
先进医疗设备和技术
-0.02%
医疗设备和用品
-0.85%
高管信息
Chairman/Chief Executive Officer/Director
Lishan Aklog
President/Chief Financial Officer/Secretary
Dennis Mcgrath
Vice Chairman/Independent Director
Michael Glennon
Other
Brian DeGuzman
Director
Tim Baxter
Director
Debra White
Independent Director
James Cox
Independent Director
Ronald Sparks
Independent Director
David Weild
暂无数据
PAVM 简况
PAVmed Inc.是一家设计、开发和商业化多样化产品的医疗器械公司。该公司产品包括PortIO、Caldus、CarpX、NextCath、DisappEAR和NextFlo。PortIO是一种无需进入中心静脉系统且不具有留置血管内组件的植入式血管通路装置。CarpX是一种治疗腕管综合征的经皮装置。NextCath是一种无需缝合、使用传统锚固技术或附加导管固定装置的自锚式导管。DisappEAR是一种抗生素洗脱可吸收耳管。该公司根据在机构设计与开发的水丝技术从事抗生素洗脱可吸收耳管的开发与商业化业务。该公司开发具有可变流量电阻器的一次性输液系统。Caldus是一种一次性组织消融装置。

微牛提供PAVmed Inc(NASDAQ-PAVM)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的PAVM股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易PAVM股票基本功能。